EDEM3 and prostate carcinoma: Here, we present proof-of-concept data to show for the first time that targeting EDEM3 may provide an opportunity to reduce levels of radio-resistance, and that the role of EDEM3 as a therapeutic target for prostate cancer warrants further investigation.